• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

A Prospective Natural History Study in Uveal Melanoma

Study Purpose

The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria.

  • - Diagnosis of uveal melanoma.
  • - Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent.
Exclusion Criteria.*None

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04588662
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Columbia University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Mariam El-Ashmawy, MD, PhD
Principal Investigator Affiliation Columbia University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Active, not recruiting
Countries Australia, Canada, Germany, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Uveal Melanoma
Additional Details

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, accounting for 85% to 95% of ocular melanoma cases. However, UM represents only about 3% to 5% of all melanomas in the United States (US). UM most commonly arises from choroidal melanocytes (85-90%), but can also arise from the iris (3-5%) and ciliary body (5-8%). The median age of diagnosis is approximately 62; however, the peak range for diagnosis is between 70 and 79. Males have a 30% greater incidence than females. A variety of putative risk factors have been identified, including the presence of light eyes, fair skin, an inability to tan, ocular melanocytosis, dysplastic nevus syndrome, and germline BRCA1-associated protein 1 (BAP1) mutations. Importantly, there are no recent or on-going multi-center natural history studies being conducted in this disease, and this effort is the only one to be launched with the goal of capturing the complete course of this disease, from diagnosis, initial management, surveillance, and treatment of recurrent disease in a national and international setting. This registry is especially important in providing such needed data.

Arms & Interventions

Arms

: Uveal Melanoma

Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Massachusetts General Hospital, Boston 4930956, Massachusetts 6254926

Status

Address

Massachusetts General Hospital

Boston 4930956, Massachusetts 6254926, 02114

Memorial Sloan Kettering Cancer Center, New York 5128581, New York 5128638

Status

Address

Memorial Sloan Kettering Cancer Center

New York 5128581, New York 5128638, 10065

Thomas Jefferson University Hospital, Philadelphia 4560349, Pennsylvania 6254927

Status

Address

Thomas Jefferson University Hospital

Philadelphia 4560349, Pennsylvania 6254927, 19107

MD Anderson Cancer Center, Houston 4699066, Texas 4736286

Status

Address

MD Anderson Cancer Center

Houston 4699066, Texas 4736286, 77030

International Sites

Royal Adelaide Hospital, Adelaide 2078025, Australia

Status

Address

Royal Adelaide Hospital

Adelaide 2078025, ,

Chatswood Eye Specialists, Chatswood 2171707, Australia

Status

Address

Chatswood Eye Specialists

Chatswood 2171707, ,

Royal Victorian Eve and Ear Hospital, East Melbourne 6952201, Australia

Status

Address

Royal Victorian Eve and Ear Hospital

East Melbourne 6952201, ,

Western Eye Specialists, Maribyrnong 2158724, Australia

Status

Address

Western Eye Specialists

Maribyrnong 2158724, ,

Pennington Eye Clinic, North Adelaide 8469169, Australia

Status

Address

Pennington Eye Clinic

North Adelaide 8469169, ,

Perth Retina, Subiaco 2060886, Australia

Status

Address

Perth Retina

Subiaco 2060886, ,

Dr. Conway Private Rooms, Sydney 2147714, Australia

Status

Address

Dr. Conway Private Rooms

Sydney 2147714, ,

St. Vincent's Hospital, Sydney 2147714, Australia

Status

Address

St. Vincent's Hospital

Sydney 2147714, ,

Princess Margaret Cancer Center, Toronto 6167865, Canada

Status

Address

Princess Margaret Cancer Center

Toronto 6167865, ,

Erlangen, Erlangen 2929567, Germany

Status

Address

Erlangen

Erlangen 2929567, ,

Clatterbridge Cancer Centre, Birkenhead 2655613, United Kingdom

Status

Address

Clatterbridge Cancer Centre

Birkenhead 2655613, ,

Mount Vernon Cancer Centre, Northwood 2641216, United Kingdom

Status

Address

Mount Vernon Cancer Centre

Northwood 2641216, ,

Sheffield, Sheffield 2638077, United Kingdom

Status

Address

Sheffield

Sheffield 2638077, ,

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact